Sildenafil preserves diastolic relaxation after reduction by l-name and increases phosphodiesterase-5 in the intercalated discs of cardiac myocytes and arterioles

Clinics

Volumn 66, Issue 7, 2011, Pages 1253-1258

  Ferreira Melo, Silvia Elaine ^a   Demacq, Caroline ^a   Lacchini, Silvia ^b   Krieger, José Eduardo ^b   Irigoyen, Maria Cláudia ^b   Moreno, Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hypertension; Immunohistochemistry; Phosphodiesterase 5 inhibitor

Indexed keywords

ENZYME INHIBITOR; N(G) NITROARGININE METHYL ESTER; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SILDENAFIL; SULFONE;

ANIMAL; ARTERIOLE; ARTICLE; BLOOD; BLOOD PRESSURE; DIASTOLE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; HEART; HEART MUSCLE CELL; HYPERTENSION; MALE; METABOLISM; PATHOPHYSIOLOGY; RAT; TIME; WISTAR RAT;

ANIMALS; ARTERIOLES; BLOOD PRESSURE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIASTOLE; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART; HYPERTENSION; MALE; MYOCYTES, CARDIAC; NG-NITROARGININE METHYL ESTER; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, WISTAR; SULFONES; TIME FACTORS;

EID: 80052165627     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000700022     Document Type: Article

References (36)

1. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, et al. Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. J Mol Cell Cardiol. 2009;46:560-567, doi: 10. 1016/j.yjmcc.2008.12.008.
2. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res. 2007;101:1084-1095, doi: 10.1161/CIRCRESAHA.107.162511.
3. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222, doi: 10.1038/ nm1175.
4. Zhang M, Koitabashi N, Nagayama T, Rambaran R, Feng N, Takimoto E, et al. Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. Cell Signal. 2008;20:2231-2236, doi: 10.1016/j.cellsig.2008. 08.012.
5. Rossoni G, Manfredi B, De Gennaro Colonna V, Berti M, Guazzi M, Berti F. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol. 2007; 150:567-576, doi: 10.1038/sj.bjp.0707131.
6. Arnal JF, el Amrani AI, Chatellier G, Menard J, Michel JB. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension. 1993;22:380-387.
7. Moreno J.H, Metze K, Zatz R, De Nucci G. Chronic nitric oxide blockade causes cardiac ischaemia but not cardiac hypertrophy: An experiment of four weeks in rats. Verh Dtsch Ges Path. 1994;78:459.
8. Pechanova O, Bernatova I, Pelouch V, Babal P. L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol Res. 1999;48:353-362.
9. Amrani M, O'Shea J, Allen NJ, Harding SE, Jayakumar J, Pepper JR, et al. Role of basal release of nitric oxide on coronary flow and mechanical performance of the isolated rat heart. J Physiol. 1992;456:681-687.
10. Jover B, Herizi A, Ventre F, Dupont M, Mimran A. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade. Hypertension. 1993;21:944-948.
11. Moreno H, Metze K, Antunes E, Zatz R, De Nucci G. Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Bas Res Cardiol. 1996;91:248-255, doi: 10.1007/BF00788911.
12. Li JS, Schiffrin EL. Resistance artery structure and neuroeffector mechanisms in hypertension induced by inhibition of nitric oxide synthase. Am J Hypertens. 1994;7:996-1004.
13. Huang M, Manning RD, Jr., LeBlanc MH, Hester RL. Overall hemodynamic studies after the chronic inhibition of endothelial-derived nitric oxide in rats. Am J Hypertens. 1995;8:358-364, doi: 10.1016/0895-7061(94)00203-N.
14. Ferreira-Melo SE, Yugar-Toledo JC, Coelho OR, De Luca IM, Tanus-Santos JE, Hyslop S, et al. Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. Eur J Pharmacol. 2006;542:141-147, doi: 10.1016/j.ejphar.2006.04.039.
15. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. Faseb J. 2001; 15:1718-1726, doi: 10.1096/fj.00-0538com.
16. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, et al. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res. 2005; 96:100-109, doi: 10.1161/01.RES.0000152262.22968.72.
17. Moreno H, Jr., Piovesan Nathan L, Pereira Costa SK, Metze K, Antunes E, Zatz R, et al. Enalapril does not prevent the myocardial ischemia caused by the chronic inhibition of nitric oxide synthesis. Eur J Pharmacol. 1995; 287:93-96, doi: 10.1016/0014-2999(95)00625-X.
18. Walker DK, Ackland MJ, James GC, Muirhead GJ, Rance DJ, Wastall P, et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica. 1999;29:297-310, doi: 10.1080/ 004982599238687.
19. Langendorff O. Untersuchungen am ü berlebenden Säugethierherzen. Pflü gers Arch Ges Physiol. 1895;61:291-332, doi: 10.1007/BF01812150.
20. Branka JE, Vallette G, Jarry A, Laboisse CL. Stimulation of mucin exocytosis from human epithelial cells by nitric oxide: evidence for a cGMP-dependent and a cGMP-independent pathway. Biochem J. 1997;323:521-524.
21. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122:216-238, doi: 10.1016/j. pharmthera.2009.02.009.
22. Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, Leroy J, et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res. 2006;99:816-828, doi: 10.1161/01.RES.0000246118.98832.04.
23. Cremers B, Scheler M, Maack C, Wendler O, Schafers HJ, Sudkamp M, et al. Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. J Cardiovasc Pharmacol. 2003;41:734-743, doi: 10.1097/ 00005344-200305000-00010.
24. Kloner RA. Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol. 2004;27:120-125, doi: 10.1002/clc.4960271306.
25. Moreno H, Jr., Metze K, Bento AC, Antunes E, Zatz R, de Nucci G. Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol. 1996;91:248-255, doi: 10.1007/BF00788911.
26. Bonow RO, Udelson JE. Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management. Ann Intern Med. 1992; 117:502-510.
27. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res. 1999;84:1020-1031.
28. Fentzke RC, Buck SH, Patel JR, Lin H, Wolska BM, Stojanovic MO, et al. Impaired cardiomyocyte relaxation and diastolic function in transgenic mice expressing slow skeletal troponin I in the heart. J Physiol. 1999;517:143-57, doi: 10.1111/j.1469-7793.1999.0143z.x.
29. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res. 2003;93:388-398, doi: 10.1161/01.RES.0000088351.58510.21.
30. Wegener JW, Nawrath H, Wolfsgruber W, Kuhbandner S, Werner C, Hofmann F, et al. cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ Res. 2002;90:18-20, doi: 10.1161/hh0102.103222.
31. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004;109:172-177, doi: 10.1161/01.CIR.0000105764.22626.B1.
32. Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation. 2006;113:2221-2228, doi: 10.1161/CIRCULATIONAHA.105.599241.
33. Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest. 1992;90:647-652, doi: 10.1172/JCI115906.
34. Deng LY, Thibault G, Schiffrin EL. Effect of hypertension induced by nitric oxide synthase inhibition on structure and function of resistance arteries in the rat. Clin Exp Hypertens. 1993;15:527-537, doi: 10.3109/ 10641969309041627.
35. Pechanova O, Bernatova I. Effect of long-term NO synthase inhibition on cyclic nucleotide content in rat tissues. Physiol Res. 1996;45:305-309.
36. 2+ channel blockers on arterial hypertension and heart ischaemic lesions induced by chronic blockade of nitric oxide in the rat. Eur J Pharmacol. 1999;373:195-200, doi: 10.1016/S0014-2999(99)00267-8.